When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MBRX - Moleculin Bio on go with mid-stage study of Annamycin for lung metastases
Moleculin Biotech Inc.
Moleculin Biotech (MBRX) perks 3% premarket after FDA signed off Investigational New Drug application for Annamycin for the treatment of soft tissue sarcoma lung metastases.This allows Moleculin to begin a Phase 1B/2 clinical trial in the U.S. for patients with soft tissue sarcoma that has metastasized to the lungs after first-line therapy for their disease.